19,931 GSK PLC Sponsored ADR $GSK Shares Sold by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC decreased its holdings in GSK PLC Sponsored ADR (NYSE:GSK) by 47.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 22,296 shares of the pharmaceutical company’s stock after selling 19,931 shares during the period. Prime Capital Investment Advisors LLC’s holdings in GSK were worth $1,074,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of GSK. Norway Savings Bank lifted its position in GSK by 7.7% during the third quarter. Norway Savings Bank now owns 14,602 shares of the pharmaceutical company’s stock valued at $703,000 after buying an additional 1,046 shares in the last quarter. Focused Alpha LLC increased its position in shares of GSK by 3.7% in the third quarter. Focused Alpha LLC now owns 6,764 shares of the pharmaceutical company’s stock worth $326,000 after acquiring an additional 242 shares in the last quarter. Jeppson Wealth Management LLC acquired a new stake in shares of GSK in the third quarter worth $218,000. CWA Asset Management Group LLC increased its position in shares of GSK by 13.7% in the third quarter. CWA Asset Management Group LLC now owns 60,317 shares of the pharmaceutical company’s stock worth $2,905,000 after acquiring an additional 7,287 shares in the last quarter. Finally, Investment Research Partners LLC increased its position in shares of GSK by 18.6% in the third quarter. Investment Research Partners LLC now owns 11,133 shares of the pharmaceutical company’s stock worth $536,000 after acquiring an additional 1,748 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

GSK has been the topic of several recent research reports. Berenberg Bank restated a “buy” rating on shares of GSK in a report on Tuesday, October 6th. Jefferies Financial Group reaffirmed a “buy” rating on shares of GSK in a research report on Monday, September 28th. Weiss Ratings downgraded GSK from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, July 29th. The Goldman Sachs Group reissued a “neutral” rating on shares of GSK in a research report on Monday, June 29th. Finally, Citigroup assumed coverage on GSK in a research report on Friday, July 24th. They issued a “neutral” rating on the stock. Four research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $55.33.

GSK Stock Performance

GSK stock opened at $50.74 on Friday. The firm has a market capitalization of $102.64 billion, a PE ratio of 15.87, a price-to-earnings-growth ratio of 2.30 and a beta of 0.33. GSK PLC Sponsored ADR has a one year low of $42.85 and a one year high of $61.69. The stock’s 50 day moving average price is $49.59 and its 200 day moving average price is $51.45. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82.

GSK (NYSE:GSK) last issued its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.09. The company had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. GSK’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the company earned $0.47 earnings per share. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, sell-side analysts expect that GSK PLC Sponsored ADR will post 4.78 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, October 8th. Stockholders of record on Friday, August 14th were paid a $0.4515 dividend. This represents a $1.81 annualized dividend and a dividend yield of 3.6%. This is a boost from GSK’s previous quarterly dividend of $0.44. The ex-dividend date was Friday, August 14th. GSK’s payout ratio is currently 55.31%.

About GSK

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.